Cargando…
Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial
The aim of this study was to evaluate the efficacy and safety of mycophenolate sodium (MPS) in patients with primary Sjögren syndrome (pSS) refractory to other immunosuppressive agents. Eleven patients with pSS were treated with MPS up to 1,440 mg daily for an observation period of 6 months in this...
Autores principales: | Willeke, Peter, Schlüter, Bernhard, Becker, Heidemarie, Schotte, Heiko, Domschke, Wolfram, Gaubitz, Markus |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246233/ https://www.ncbi.nlm.nih.gov/pubmed/17986340 http://dx.doi.org/10.1186/ar2322 |
Ejemplares similares
-
Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren's syndrome
por: Willeke, Peter, et al.
Publicado: (2007) -
Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis
por: Schotte, Heiko, et al.
Publicado: (2015) -
Mycophenolate for the Treatment of Primary Sjögren’s Syndrome
por: Chen, Weiqian, et al.
Publicado: (2020) -
Differential effects of cyclophosphamide and mycophenolate mofetil on cellular and serological parameters in patients with systemic lupus erythematosus
por: Fassbinder, Till, et al.
Publicado: (2015) -
Intravenous Immunoglobulin and Mycophenolate Mofetil for Long-Standing Sensory Neuronopathy in Sjögren's Syndrome
por: Danieli, Maria Giovanna, et al.
Publicado: (2012)